HUP0300342A2 - Carvedilol hidrofil molekuláris diszperziós oldatait tartalmazó készítmények, eljárás az előállításukra és alkalmazásuk - Google Patents

Carvedilol hidrofil molekuláris diszperziós oldatait tartalmazó készítmények, eljárás az előállításukra és alkalmazásuk

Info

Publication number
HUP0300342A2
HUP0300342A2 HU0300342A HUP0300342A HUP0300342A2 HU P0300342 A2 HUP0300342 A2 HU P0300342A2 HU 0300342 A HU0300342 A HU 0300342A HU P0300342 A HUP0300342 A HU P0300342A HU P0300342 A2 HUP0300342 A2 HU P0300342A2
Authority
HU
Hungary
Prior art keywords
carvedilol
preparation
compositions containing
containing hydrophilic
hydrophilic molecular
Prior art date
Application number
HU0300342A
Other languages
English (en)
Inventor
Rolf-Dieter Gabel
Günter Neugebauer
Walter Preis
Alexander Wirl
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0300342(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of HUP0300342A2 publication Critical patent/HUP0300342A2/hu
Publication of HUP0300342A3 publication Critical patent/HUP0300342A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány gyógyászatilag alkalmas készítményre vonatkozik, amelycarvedilolt vagy gyógyászatilag alkalmas sóját molekuláris diszperzióformájában eloszlatva 5 tömeg/tömeg%-nál nagyobb koncentrációbantartalmaz. A találmány továbbá a fenti kompozíciót magában foglalógyógyászati adagolási formákra és ezeknek betegségek (pl. hipertenzió,szívelégtelenség vagy angina pectoris) kezelésére és/vagy megelőzéséretörténő felhasználására vonatkozik. Ó
HU0300342A 2000-04-03 2001-03-28 Compositions containing hydrophilic molecular disperse solutions of carvedilol, process for their preparation and their use HUP0300342A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00107093 2000-04-03
PCT/EP2001/003502 WO2001074357A1 (en) 2000-04-03 2001-03-28 Hydrophilic molecular disperse solutions of carvedilol

Publications (2)

Publication Number Publication Date
HUP0300342A2 true HUP0300342A2 (hu) 2003-06-28
HUP0300342A3 HUP0300342A3 (en) 2005-07-28

Family

ID=8168348

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300342A HUP0300342A3 (en) 2000-04-03 2001-03-28 Compositions containing hydrophilic molecular disperse solutions of carvedilol, process for their preparation and their use

Country Status (24)

Country Link
US (3) US20010036959A1 (hu)
EP (1) EP1272179B1 (hu)
JP (1) JP2003528915A (hu)
KR (1) KR100478793B1 (hu)
CN (1) CN1189171C (hu)
AR (1) AR029825A1 (hu)
AT (1) ATE450257T1 (hu)
AU (2) AU5622701A (hu)
BR (1) BR0109779A (hu)
CA (1) CA2401910C (hu)
CZ (1) CZ20023625A3 (hu)
DE (1) DE60140662D1 (hu)
HR (1) HRP20020777A2 (hu)
HU (1) HUP0300342A3 (hu)
IL (1) IL151642A0 (hu)
MA (1) MA26888A1 (hu)
MX (1) MXPA02009725A (hu)
NO (1) NO20024733L (hu)
NZ (1) NZ521232A (hu)
PL (1) PL358103A1 (hu)
RU (1) RU2248204C2 (hu)
WO (1) WO2001074357A1 (hu)
YU (1) YU72602A (hu)
ZA (1) ZA200207304B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1067910T3 (da) * 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
EP1929998A3 (en) * 2001-09-21 2008-11-26 Egalet A/S Controlled release solid dispersions of carvedilol
RU2308449C2 (ru) * 2001-09-28 2007-10-20 Ф.Хоффманн-Ля Рош Аг Псевдополиморфные формы карведилола
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
US20050148779A1 (en) * 2002-04-30 2005-07-07 Wei Chen Carvedilol monocitrate monohydrate
EP1501500A2 (en) * 2002-05-03 2005-02-02 SmithKline Beecham Pharmco Puerto Rico, Inc. Carvedilol formulations
WO2004002472A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
CA2492060C (en) * 2002-06-27 2011-11-01 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
EP1592760A4 (en) 2003-01-31 2009-08-12 Smithkline Beecham Corp AS FIXED DISPERSIONS, COMPOSITIONS
WO2004084869A1 (en) 2003-03-26 2004-10-07 Egalet A/S Matrix compositions for controlled delivery of drug substances
DE602004031096D1 (de) 2003-03-26 2011-03-03 Egalet As Morphin-system mit kontrollierter freisetzung
WO2005004848A1 (en) * 2003-07-09 2005-01-20 Chong Kun Dang Pharmaceutical Corp. The solid dispersion of tacrolimus
SI1663217T1 (sl) * 2003-08-29 2010-10-29 Lifecycle Pharma As Trdne disperzije, ki vsebujejo takrolimus
CA2537041C (en) 2003-08-29 2012-04-03 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
EP1701703B1 (en) * 2003-12-31 2011-03-09 Bend Research, Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers and stabilizing polymers
EP1895989A2 (en) * 2005-06-03 2008-03-12 Egalet A/S A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080138404A1 (en) * 2006-12-06 2008-06-12 Biovail Laboratories International S.R.L. Extended release formulations of carvedilol
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
ATE539769T1 (de) 2008-03-04 2012-01-15 Lupin Ltd Stabile pharmazeutische zusammensetzungen mit carvedilol
ES2330404B1 (es) * 2008-05-19 2010-09-22 Universidad De Barcelona Solucion acuosa para la preservacion de tejidos y organos.
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
WO2011154009A1 (en) * 2010-06-10 2011-12-15 Lifecycle Pharma A/S Composition comprising an active principle in an amorphous form and a porous adsorbent material
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
ATE275394T1 (de) * 1997-03-11 2004-09-15 Arakis Ltd R- und s- enantiomere getrennteteile enthaltende dosierungsformen
DE19809242A1 (de) * 1998-03-05 1999-09-09 Basf Ag Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19816036A1 (de) * 1998-04-09 1999-10-14 Roche Diagnostics Gmbh Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
US6852337B2 (en) * 1998-04-09 2005-02-08 Roche Diagnostics Gmbh Carvedilol-galenics
US6664284B2 (en) * 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1474133A4 (en) * 2002-01-15 2006-02-01 Teva Pharma SOLID CRYSTALLINE CARVEDILOL BODIES AND METHODS OF MAKING SAME

Also Published As

Publication number Publication date
US20010036959A1 (en) 2001-11-01
CN1420771A (zh) 2003-05-28
CZ20023625A3 (cs) 2003-04-16
PL358103A1 (en) 2004-08-09
CA2401910C (en) 2008-04-15
KR100478793B1 (ko) 2005-03-24
NO20024733D0 (no) 2002-10-02
RU2248204C2 (ru) 2005-03-20
JP2003528915A (ja) 2003-09-30
YU72602A (sh) 2005-03-15
AU2001256227B2 (en) 2005-09-01
AU5622701A (en) 2001-10-15
ZA200207304B (en) 2003-12-11
NO20024733L (no) 2002-10-02
MXPA02009725A (es) 2003-03-27
CN1189171C (zh) 2005-02-16
WO2001074357A1 (en) 2001-10-11
EP1272179B1 (en) 2009-12-02
NZ521232A (en) 2004-05-28
BR0109779A (pt) 2003-01-21
AR029825A1 (es) 2003-07-16
MA26888A1 (fr) 2004-12-20
CA2401910A1 (en) 2001-10-11
EP1272179A1 (en) 2003-01-08
ATE450257T1 (de) 2009-12-15
DE60140662D1 (de) 2010-01-14
HRP20020777A2 (en) 2004-12-31
RU2002129571A (ru) 2004-03-27
US20050271721A1 (en) 2005-12-08
IL151642A0 (en) 2003-04-10
KR20030019339A (ko) 2003-03-06
HUP0300342A3 (en) 2005-07-28
US20030004205A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
HUP0300342A2 (hu) Carvedilol hidrofil molekuláris diszperziós oldatait tartalmazó készítmények, eljárás az előállításukra és alkalmazásuk
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
ATE294510T1 (de) Netzwerk-bildende und pektin-enthaltende zubereitung
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
HUP0301452A2 (hu) Fotokemoterápiás szert és mukoadhéziós szert tartalmazó gyógyszerkészítmény és alkalmazása
DK1435909T3 (da) Stabil sammensætning indeholdende partikler i en frossen vandig matrix
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
NO20034230L (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
MY147373A (en) Piperazine derivatives as antimalarial agents
HUP0204451A2 (hu) Nimesulidot tartalmazó szabályozott hatóanyag-leadású készítmények
TR200001542T2 (tr) Mide fundusunu gevşetici özelliklere sahip (benzodioksan, benzofuran veya benzopiran) türevleri.
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
NO20010833L (no) Orale mukoadhesive sammensetninger inneholdende gastrointestinale aktive bestanddeler
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
HUP0402318A2 (hu) Ciklosporint tartalmazó gyógyászati készítmény és alkalmazása
HUP0301177A2 (hu) Ionerősségtől független, nyújtott hatóanyag-leadású gyógyszerkészítmények
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
HUP0004345A2 (hu) Új orális, karvedilolt tartalmazó gyógyszerkészítmény
Pujarern et al. Lesson Learned from Antiseptic Mouthwash in COVID-19 Pandemic Then, Now and Future: A Systematic Review.
HUP0401940A2 (hu) Diabetikus neuropátia esetében alkalmazható gyógyszerkészítmény

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees